Harada N, Inagaki N. Role of clock genes in insulin secretion. J Diabetes Investig. 2016 Nov;7(6):822-823. doi: 10.1111/jdi.12517. Epub 2016 Apr 26.
Joo E, Fukushima T, Harada N, Reed JC, Matsuzawa SI, Inagaki N. Ubc13 haploinsufficiency protects against age-related insulin resistance and high-fat diet-induced obesity. Sci Rep. 2016 Oct 31;6:35983. doi: 10.1038/srep35983.
Ogura K, Ogura M, Shoji T, Sato Y, Tahara Y, Yamano G, Sato H, Sugizaki K, Fujita N, Tatsuoka H, Usui R, Mukai E, Fujimoto S, Inagaki N, Nagashima K. Oral Administration of Apple Procyanidins Ameliorates Insulin Resistance via Suppression of Pro-Inflammatory Cytokine Expression in Liver of Diabetic ob/ob Mice. J Agric Food Chem. 2016 Nov 23;64(46):8857-8865. Epub 2016 Nov 10.
Ueda Y, Yasoda A, Yamashita Y, Kanai Y, Hirota K, Yamauchi I, Kondo E, Sakane Y, Yamanaka S, Nakao K, Fujii T, Inagaki N. C-type natriuretic peptide restores impaired skeletal growth in a murine model of glucocorticoid-induced growth retardation. Bone. 2016 Nov;92:157-167. doi: 10.1016/j.bone.2016.08.026. Epub 2016 Sep 2.
Asai K, Kobayashi T, Miyata H, Tanaka Y, Okada Y, Sakai K, Negoro H, Kamba T, Tsuji H, Shide K, Yanagita M, Inagaki N, Ogawa O. The Short-Term Impact of Dietary Counseling on Sodium Intake and Blood Pressure in Renal Allograft Recipients. Prog Transplant. 2016 Aug 28. pii: 1526924816664084. [Epub ahead of print]
Saito R, Takeuchi A, Himeno Y, Inagaki N, Matsuoka S. A simulation study on the constancy of cardiac energy metabolites during workload transition. J Physiol. 2016 Dec 1;594(23):6929-6945. doi: 10.1113/JP272598. Epub 2016 Oct 2.
Inagaki N, Sheu WH, Owens DR, Crowe S, Bhandari A, Gong Y, Patel S. Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. J Diabetes Complications. 2016 Nov – Dec;30(8):1622-1630. doi: 10.1016/j.jdiacomp.2016.07.002. Epub 2016 Jul 15.
Inagaki N, Araki E, Oura T, Matsui A, Takeuchi M, Tanizawa Y. The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2016 Dec;18(12):1279-1282. doi: 10.1111/dom.12758. Epub 2016 Sep 8.
Nishi K, Sato Y, Ohno M, Hiraoka Y, Saijo S, Sakamoto J, Chen PM, Morita Y, Matsuda S, Iwasaki K, Sugizaki K, Harada N, Mukumoto Y, Kiyonari H, Furuyama K, Kawaguchi Y, Uemoto S, Kita T, Inagaki N, Kimura T, Nishi E. Nardilysin Is Required for Maintaining Pancreatic β-Cell Function. Diabetes. 2016 Oct;65(10):3015-27. doi: 10.2337/db16-0178. Epub 2016 Jul 6.
Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016 Jun 18;15:89. doi: 10.1186/s12933-016-0407-4.
Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, Inagaki N, Uemoto S. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition. 2016 Nov-Dec;32(11-12):1200-5. doi: 10.1016/j.nut.2016.04.003. Epub 2016 May 4.
Ueda-Sakane Y, Kanamoto N, Fushimi Y, Tanaka-Mizuno S, Yasuno S, Miura M, Sone M, Yasoda A, Okada T, Togashi K, Nakao K, Inagaki N. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves’ ophthalmopathy. Endocr J. 2016 Aug 31;63(8):703-14. doi: 10.1507/endocrj.EJ16-0038. Epub 2016 Jun 5.
Yamane S, Harada N, Inagaki N. Mechanisms of fat-induced gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide secretion from K cells. J Diabetes Investig. 2016 Apr;7 Suppl 1:20-6. doi: 10.1111/jdi.12467. Epub 2016 Mar 14. Review.
Noto H, Tanizawa Y, Aizawa T, Sone H, Yoshioka N, Terauchi Y, Inagaki N, Noda M. Cluster-randomized trial to improve the quality of diabetes management: The study for the efficacy assessment of the standard diabetes manual (SEAS-DM). J Diabetes Investig. 2016 Jul;7(4):539-43. doi: 10.1111/jdi.12455. Epub 2016 Jan 22.
Inagaki N, Sano H, Seki Y, Kuroda S, Kaku K. Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study. J Diabetes Investig. 2016 Sep;7(5):718-26. doi: 10.1111/jdi.12499. Epub 2016 Mar 28.
Sato H, Nagashima K, Ogura M, Sato Y, Tahara Y, Ogura K, Yamano G, Sugizaki K, Fujita N, Tatsuoka H, Usui R, Mukai E, Fujimoto S, Inagaki N. Src regulates insulin secretion and glucose metabolism by influencing subcellular localization of glucokinase in pancreatic β-cells. J Diabetes Investig. 2016 Mar;7(2):171-8. doi: 10.1111/jdi.12407. Epub 2015 Sep 13.
Yamane S, Inagaki N. Control of intestinal stem cell fate: A novel approach to treating diabetes. J Diabetes Investig. 2016 Mar;7(2):166-8. doi: 10.1111/jdi.12390. Epub 2015 Aug 9.
Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Kakiuchi H, Samukawa Y. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials. Clin Ther. 2016 Apr;38(4):843-862.e9. doi: 10.1016/j.clinthera.2016.01.017. Epub 2016 Mar 25.
Yamashita Y, Yamada-Goto N, Katsuura G, Ochi Y, Kanai Y, Miyazaki Y, Kuwahara K, Kanamoto N, Miura M, Yasoda A, Ohinata K, Inagaki N, Nakao K. Brain-specific natriuretic peptide receptor-B deletion attenuates high-fat diet-induced visceral and hepatic lipid deposition in mice. Peptides. 2016 Jul;81:38-50. doi: 10.1016/j.peptides.2016.03.014. Epub 2016 Mar 25.
Mori E, Fujikura J, Noguchi M, Nakao K, Matsubara M, Sone M, Taura D, Kusakabe T, Ebihara K, Tanaka T, Hosoda K, Takahashi K, Asaka I, Inagaki N, Nakao K. Impaired adipogenic capacity in induced pluripotent stem cells from lipodystrophic patients with BSCL2 mutations. Metabolism. 2016 Apr;65(4):543-56. doi: 10.1016/j.metabol.2015.12.015. Epub 2016 Jan 7.
Kondo Y, Harada N, Hamasaki A, Kaneko S, Yasuda K, Ogawa E, Harashima S, Yoneda H, Fujita Y, Kitano N, Nakamura Y, Matsuo F, Shinji M, Hinotsu S, Nakayama T, Inagaki N; MAIKO Study group.. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Diabetol Metab Syndr. 2016 Feb 27;8:15. doi: 10.1186/s13098-016-0131-y. eCollection 2016.
Aoyama-Sasabe S, Fukushima M, Xin X, Taniguchi A, Nakai Y, Mitsui R, Takahashi Y, Tsuji H, Yabe D, Yasuda K, Kurose T, Inagaki N, Seino Y. Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance. J Diabetes Res. 2016;2016:1298601. doi: 10.1155/2016/1298601. Epub 2015 Dec 15.
Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22.